Workflow
Maider Medical Industry Equipment (688310)
icon
Search documents
迈得医疗(688310) - 2020 Q3 - 季度财报
2020-10-26 16:00
2020 年第三季度报告 公司代码:688310 公司简称:迈得医疗 迈得医疗工业设备股份有限公司 2020 年第三季度报告 1 / 26 $$\mathbb{H}\,{\overline{{\exists\mathbb{K}}}}$$ | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 7 | | 四、 | 附录 9 | 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位:元 币种:人民币 | | 本报告期末 | | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | --- | | | | | | 减(%) | | | 总资产 | 803,161,648.05 | | 804,416,386.84 | | -0.16 | | 归属于上市公司 股东的净资产 | 729,883,461.45 | | 707,270,587.76 | | 3.20 | | | 年初至报告期末 | | 上年初至上年报告期末 | 比上年同期增减(%) | | | | ( ...
迈得医疗(688310) - 2020 Q2 - 季度财报
2020-08-24 16:00
Financial Performance - The company's operating revenue for the first half of 2020 was RMB 114,333,626.10, representing a 43.87% increase compared to RMB 79,468,088.68 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2020 was RMB 41,597,733.71, a significant increase of 165.91% from RMB 15,643,522.59 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 38,410,081.78, which is a 354.66% increase compared to RMB 8,448,168.67 in the same period last year[19]. - The net cash flow from operating activities reached RMB 53,560,609.10, up 364.21% from RMB 11,538,090.87 in the previous year[19]. - Basic earnings per share for the first half of 2020 were RMB 0.50, doubling from RMB 0.25 in the same period last year[20]. - The gross margin for the main business was 65.45% in the first half of 2020, up from 46.56% in the same period of 2019[85]. - The company achieved a revenue growth of 43.87% year-on-year, with mask machine business accounting for 73.50% of total revenue[74]. Research and Development - The research and development expenditure accounted for 11.41% of operating revenue, a decrease of 1.37 percentage points from 12.78% in the previous year[20]. - The company has established R&D bases in Tianjin and Germany to support ongoing technological advancements[75]. - Total R&D expenses for the period amounted to ¥13,041,556.07, representing 11.41% of total revenue[55]. - The company holds 154 invention patents, 73 utility model patents, and 26 software copyrights, reflecting its strong innovation capabilities[46]. - The company is focusing on the development of intelligent production lines, transitioning from single machines to fully automated production systems[82]. Market and Product Development - The company successfully developed an automatic mask machine in response to market demand, contributing significantly to revenue during the reporting period[19]. - The company has launched several intelligent control systems for medical equipment, enhancing its product offerings and contributing to revenue from customized medical software[32]. - The company is exploring new markets in orthopedic and high-value medical consumables, indicating a strategic expansion into new segments[84]. - The company plans to optimize and expand its safety infusion product line and explore the blood purification consumables segment in the second half of 2020[49]. - The company is developing a mask machine that can produce over 100 units per minute, targeting the mid-to-high-end market[59]. Financial Position and Assets - The company's total assets at the end of the reporting period were RMB 813,212,754.09, reflecting a 1.09% increase from RMB 804,416,386.84 at the end of the previous year[19]. - Cash and cash equivalents increased to ¥452,971,573.99, representing 55.70% of total assets, a significant rise of 1,732.50% compared to the previous year[102]. - Inventory reached ¥132,002,296.90, accounting for 16.23% of total assets, with a year-on-year increase of 57.91% due to higher material purchases for existing orders[102]. - The company reported a total equity of ¥733,885,132.82, an increase from ¥717,560,494.85, showing a growth of 2.3%[168]. Shareholder and Governance - The company has committed to maintaining shareholding restrictions for its major shareholders for a period of 36 months post-IPO[108]. - The company will extend the lock-up period by an additional six months if the stock price falls below the IPO price for 20 consecutive trading days[109]. - The company has established a buyback plan if the stock price does not exceed the audited net asset value per share for 10 consecutive trading days[110]. - The company emphasizes the importance of maintaining shareholder confidence through these lock-up and transfer restrictions[110]. - The total number of ordinary shareholders as of the end of the reporting period is 5,413[148]. Risks and Challenges - The company faces potential risks related to the performance of major contracts, particularly with ARSMED, which has not yet accepted delivery of equipment valued at 2.43 million USD[89]. - The company anticipates a potential decline in mask machine gross margins as the pandemic stabilizes, which could negatively impact overall gross margins[85]. - The company is actively expanding its overseas business, but faces risks from international relations and potential trade sanctions[92]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[170]. - The company is focusing on expanding its market presence and exploring new strategies for growth[199]. - Future guidance suggests a continued upward trend in revenue and market share[199].
迈得医疗(688310) - 2020 Q1 - 季度财报
2020-04-24 16:00
2020 年第一季度报告 公司代码:688310 公司简称:迈得医疗 迈得医疗工业设备股份有限公司 2020 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2020 年第一季度报告 一、 重要提示 单位:元 币种:人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | -2,940.30 | | | 越权审批,或无正式批准文件,或 | | | | 偶发性的税收返还、减免 | | | | 计入当期损益的政府补助,但与公 | | | | 司正常经营业务密切相关,符合国 | 2,817,219.88 | | | 家政策规定、按照一定标准定额或 | | | | 定量持续享受的政府补助除外 | | | | 计入当期损益的对非金融企业收取 | | | | 的资金占用费 | | | | 企业取得子公司、联营企业及合营 | | | | 企业的投资成本小于取得投资时应 | | | | 享有被投资单位可辨认净资产公允 | | | | ...
迈得医疗(688310) - 2019 Q4 - 年度财报
2020-04-24 16:00
Financial Performance - The company's operating revenue for 2019 was approximately ¥209.55 million, a decrease of 2.49% compared to 2018[23]. - The net profit attributable to shareholders decreased by 16.53% to approximately ¥46.75 million in 2019[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 25.12% to approximately ¥36.76 million[23]. - The net cash flow from operating activities decreased significantly by 54.61% to approximately ¥14.14 million[25]. - The total assets increased by 144.56% to approximately ¥804.42 million at the end of 2019 compared to the end of 2018[23]. - The net assets attributable to shareholders increased by 179.17% to approximately ¥707.27 million at the end of 2019[23]. - Basic and diluted earnings per share decreased by 17.98% to ¥0.73 in 2019[24]. - The gross profit margin for the reporting period was 48.53%, remaining stable compared to the previous year[100]. - The company achieved a total R&D investment of CNY 20,567,308.97, which accounts for 9.82% of its operating revenue[64]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 3.5 per 10 shares to all shareholders, which is a total distribution of approximately RMB 35 million based on the total share capital at the time of the distribution[8]. - The cash dividend distribution for 2019 accounts for 62.58% of the net profit attributable to shareholders, compared to 90.13% in 2018 and 56.14% in 2017[136]. - The company has established a three-year shareholder return plan (2019-2021) to provide stable investment returns and maximize shareholder value[133]. - The company has established a profit distribution policy detailed in the Articles of Association, which was approved at the 2018 annual shareholders' meeting, outlining a three-year dividend return plan for 2019-2021[149]. Risk Management - The company has outlined potential risks in its operations and corresponding countermeasures in the report, emphasizing the importance of risk management[5]. - The company has a comprehensive risk management strategy detailed in the report, which is crucial for maintaining operational stability[5]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a substantive commitment to investors[10]. - The company faces risks related to rapid technological updates and the need for continuous innovation to maintain competitive advantage[87]. Research and Development - The R&D expenditure as a percentage of operating revenue increased by 0.78 percentage points to 9.82%[24]. - The company has developed seven core technologies in the field of medical consumables intelligent equipment, maintaining a leading position both domestically and internationally[58]. - The company has obtained 35 patents related to its core technologies, including 24 invention patents, enhancing its competitive edge in the market[59]. - The company has established R&D bases in Tianjin and Germany to enhance technological innovation[83]. - The company has developed new technologies including insulin needle bonding technology and automatic blood collection needle technology during the reporting period[83]. Market Position and Strategy - The company focuses on the research, production, and sales of intelligent equipment for medical consumables, specifically in the fields of safety infusion and blood purification[35]. - The company is recognized as one of the earliest manufacturers of medical consumables intelligent equipment in China, holding a leading position in terms of operational scale, R&D capabilities, and product innovation[48]. - The company is actively exploring international markets, but faces potential risks from geopolitical tensions and the ongoing impact of the COVID-19 pandemic[95]. - The company aims to enhance its production and R&D capabilities through fundraising projects, targeting growth in the automation equipment sector[126]. Compliance and Governance - The company has a commitment to maintaining shareholding restrictions regardless of changes in position or resignation[142]. - The company emphasizes compliance with legal regulations regarding share transfers[141]. - The company has established investor relations and information disclosure management systems to ensure timely and accurate information for investors[172]. - The company is committed to protecting minority shareholder rights and improving investor relations management[130]. Operational Challenges - The company experienced a significant increase in expenses due to higher personnel costs and increased travel and service fees[25]. - The company reported a significant decline in cash flow from investment activities, amounting to a net outflow of CNY 402.50 million[99]. - Operating cash flow decreased by 54.61% year-on-year, mainly due to delays in the acceptance of large orders and increased personnel costs[116]. Shareholder Structure - The top shareholder, Lin Junhua, holds 39,986,000 shares, representing 47.83% of the total shares[191]. - The second largest shareholder, Chen Wanshun, owns 14,230,000 shares, accounting for 17.02%[191]. - The total number of shares held by the top ten shareholders is 64,214,751, which constitutes a significant portion of the company's equity[196]. - The company has a lock-up period for major shareholders, with Lin Junhua's shares locked for 36 months starting from December 3, 2022[193].